Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Lluis Ballell Pages

Julia Castro Pichel

Esther Pilar Fernandez Velando

Raquel Fernandez Menendez

Silvia Gonzalez Del Valle

David Barros Aguirre

Robert H Bates

Alfonso Mendoza Losana

Kevin Pethe

Jorge Esquivias Provencio

Matthew James Wolfendale

The present invention relates to the use in therapy of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof, to pharmaceutically acceptable salts of 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione and to pharmaceutical formulations comprising 6-((4-(2,3-dimethylphenoxy)piperidin-1-yl)methyl)pyrimidine-2,4(1H,3H)-dione or a pharmaceutically acceptable salt thereof.

Antituberculosis agent

A compound of Formula (I) wherein: either X is N and Y is CRor X is C and Y is S; Z is selected from N and CH; Ris selected from H and Me; Ris selected from H, OH, OMe and Me; each Ris independently selected from Calkyl, F, Cl, Br, CFand NH; Ris selected from Me, CF, NOand CHF; Ris selected from H, Me and CHF; Ris selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

(Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds

Growing community of inventors

Madrid, Spain

Lluis Ballell Pages